Hydronidone - Shanghai Genomics

Drug Profile

Hydronidone - Shanghai Genomics

Alternative Names: F-351

Latest Information Update: 25 Apr 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Shanghai Genomics
  • Class Antifibrotics; Nonsteroidal anti-inflammatories; Small molecules
  • Mechanism of Action Collagen inhibitors; Fibroblast growth factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Hepatic fibrosis
  • Preclinical Renal failure
  • Discontinued Pulmonary fibrosis

Most Recent Events

  • 24 Apr 2018 Phase-I clinical trials in Hepatic fibrosis in USA (PO)
  • 09 Oct 2017 GNI USA plans an open-label phase I trial to determine safety, tolerability and pharmacokinetics of single and repeated doses of hydronidone in USA in early 2018
  • 29 Sep 2017 GNI USA receives the US FDA clearance for the Investigational New Drug application for clinical trials in Hepatic fibrosis in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top